Oxygenta Pharma Approves Audited Financial Results for FY26

Oxygenta Pharmaceutical Ltd's board meeting on May 23, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. The board also appointed Mr. Amireddy Venkatesu Reddy as an Additional Director (Executive category) for 3 years and Mr. Janardhana Reddy Yeddula as an Additional Director (Independent Category) for 5 years, both subject to shareholder approval. Additionally, M/s. Suryachandra & Associates were appointed as Internal Auditors for FY 2026-27, and M/s. Aakanksha Dubey & Co. was appointed as Scrutinizer for the e-voting process at the upcoming Annual General Meeting.